July 25, 2018 02:42 PM EDT

Acorda shares tank as appeals court refuses injunction against cheap Ampyra knockoffs

John Carroll

Editor & Founder

Acorda has suffered a fresh setback in its last-ditch attempt to stop a generic version of its multiple sclerosis drug Ampyra from hitting the market …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Acorda shares tank as appeals court refuses injunction against cheap Ampyra knockoffs

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

WuXi companies may sell units impacted by Biosecure — report

Biotech's third quarter was relatively bright — with a few caveats

EMA reviews hair loss products following concerns about suicidal thoughts

RSV vaccines off to a sluggish start in US this season, with volumes behind 2023

Sanofi sells rare disease drug Enjaymo to Recordati for $825M upfront

3 Tiers for AAV Potency Assay Development Success

Acor­da shares tank as ap­peals court re­fus­es in­junc­tion against cheap Ampyra knock­offs

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Acorda shares tank as appeals court refuses injunction against cheap Ampyra knockoffs